Skip to main content
SpringerLink
Log in

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).

Methods

TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).

Results

Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p = 0.04), and prediction of OS was even better (87 % vs. 60 %, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.

Conclusion

Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50 Suppl 1:21S–30S.

    Article  PubMed  CAS  Google Scholar 

  2. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010;21:1486–91.

    Article  PubMed  CAS  Google Scholar 

  3. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

    Article  PubMed  CAS  Google Scholar 

  4. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27:5573–9.

    Article  PubMed  Google Scholar 

  5. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7.

    Article  PubMed  Google Scholar 

  6. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435–44.

    Article  PubMed  Google Scholar 

  7. Paone G, Itti E, Haioun C, Gaulard P, Dupuis J, Lin C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745–50.

    Article  PubMed  Google Scholar 

  8. Meignan MA, Sasanelli MC, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.

    Article  PubMed  CAS  Google Scholar 

  9. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20.

    Article  PubMed  Google Scholar 

  10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  11. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012;30:194–9.

    Article  PubMed  Google Scholar 

  12. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50–8.

    Article  PubMed  CAS  Google Scholar 

  13. Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24:208–14.

    Article  PubMed  CAS  Google Scholar 

  14. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272–81.

    PubMed  CAS  PubMed Central  Google Scholar 

  16. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–9.

    Article  PubMed  CAS  Google Scholar 

  17. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50 Suppl 1:11S–20S.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Nuclear Medicine and Lymphoid Malignancies Unit, Henri Mondor Hospital, Paris-Est University, 51 Ave. du Mal de Lattre, 94010, Créteil, France

    Myriam Sasanelli, Michel Meignan, Corinne Haioun & Emmanuel Itti

  2. Nuclear Medicine and Hematology, Georges-François Leclerc Center, Le Bocage Hospital, Dijon, France

    Alina Berriolo-Riedinger & René-Olivier Casasnovas

  3. Nuclear Medicine and Hematology, Santa Croce e Carle Hospital, Cuneo, Italy

    Alberto Biggi & Andrea Gallamini

  4. Nuclear Medicine and Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

    Barry A. Siegel & Amanda F. Cashen

  5. Nuclear Medicine and Hematology, Henri Becquerel Center, Rouen, France

    Pierre Véra & Hervé Tilly

  6. Nuclear Medicine, Santa Maria Nuova Hospital-IRCCS, Reggio Emilia, Italy

    Annibale Versari

Authors
  1. Myriam Sasanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Meignan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Corinne Haioun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alina Berriolo-Riedinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. René-Olivier Casasnovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alberto Biggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Gallamini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barry A. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amanda F. Cashen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre Véra
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hervé Tilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Annibale Versari
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emmanuel Itti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel Itti.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sasanelli, M., Meignan, M., Haioun, C. et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 41, 2017–2022 (2014). https://doi.org/10.1007/s00259-014-2822-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2822-7

Key words

Search

Navigation